New shot aims to stop painful shingles outbreaks
NCT ID NCT07311148
Summary
This study is testing a new shingles vaccine called LYB004 to see how well it triggers an immune response and how safe it is. It will involve 840 adults in China aged 40 and older, who will receive different versions of the vaccine or a placebo. The main goal is to measure the body's antibody response and track any side effects after vaccination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHINGLES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hengnan County Center for Disease Control and Prevention
Hengyang, Hunan, China
Conditions
Explore the condition pages connected to this study.